

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

VOLUNTARY ANNOUNCEMENT CONDITIONAL NEW DRUG APPLICATION OF EAL® ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Immunotech Biopharm Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company regarding the recent business updates of the Group. Reference is made to the Company’s announcement dated 28 February 2025 (“**February Announcement**”) relating to the recent development of the Group’s core product candidate, EAL®. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the February Announcement.

The board of directors (the “**Board**”) of the Company is pleased to announce that the conditional new drug application (“**NDA**”) of EAL®, the core product candidate of the Company, has been accepted by the Centre for Drug Evaluation (the “**CDE**”) of the National Medical Products Administration of China (the “**NMPA**”).

INFORMATION ON EAL®

EAL® is a multi-target cellular immunotherapy product with more than a decade of track record of clinical application in the treatment of various types of cancer. EAL® is a preparation of activated and expanded T cells originally taken from a patient’s autologous peripheral blood and cultured using patented methods. The main active component of the product is CD8+ cytotoxic T cells, whose surface marker is the CD3 molecule.

ABOUT THE GROUP

The Group is a leading cellular immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T cell immunotherapy. Since its establishment in 2006, it has focused on research and development and clinical applications of cellular immunotherapy drugs for cancers and other major diseases, by applying advanced theories in immunology, cell biology, and genetics. Its product pipeline features major classes of cellular immunotherapy products, including both non-genetically-modified and genetically-modified products, as well as both multi-target and single-target products. Its main product candidates include EAL[®], the CAR-T cell series and the TCR-T cell series. To learn more about the Company, please visit www.eaal.net.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Group cannot guarantee that the Company will be able to obtain further approval for, or ultimately market, EAL[®], successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 31 March 2025

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu as executive Director, Mr Tao Ran, Mr Wang Ruihua, Mr Yang Fan and Mr Wang Donghu as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.